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Background: The current therapeutic arsenal still does not fulfill the therapeutic 
needs of inflammatory bowel disease patients. Although new drugs are 
constantly being developed, many will never reach the market. In this review 
we will search for reasons for discontinuing promising clinical trials and offer 
recommendation for future trials. Methods: The website clinicaltrials.gov was 
searched for interventional trials on novel inflammatory bowel disease therapies. 
Included were discontinued ‘Crohn’s disease’ and/or ‘colitis, ulcerative’ trials, 
started between July 1996 and October 2011 and discontinued. Pubmed was 
searched for publications to elucidate reasons for discontinuation. Results: 
One hundred and ninety one novel drug trials were published on clinicaltrials.
gov, of which 24 (12.6%) were interrupted. The most common reason for 
discontinuation was lack of efficacy. Conclusion: Translation from bench to 
bedside is not always feasible, animal models come with restrictions. For better 
treatments, personalized medicine will be the future.
Keywords: clinical trials • Crohn’s disease • inflammatory bowel disease 
• translational research • trial design • ulcerative colitis
Inflammatory bowel disease (IBD) is a chronic disease of the gastrointestinal tract 
and comprises of Crohn’s disease (CD), ulcerative colitis (UC) and unclassified 
colitis. IBD patients experience periods of remission of their disease but are also 
prone to relapse and it was demonstrated that IBD can evolve to a more compli-
cated phenotype [1–4]. The highest incidence rates are reported from Northern 
Europe, the UK and North America, ranging from 6.6 to 15.6 cases per 100,000 
person years [5]. The impact on physical, social, as well as the emotional well-being 
of patients is substantial and the disease profoundly decreases the quality of life [6].
At present, no therapeutic intervention exists that can lead to a definitive cure. 
As such, the current treatment goal is to provide long-term remission. Towards 
this aim, the armamentarium has been expanded with novel and more potent 
drugs. Although many drugs have been used in the treatment of IBD, none has, so 
far, been shown to modify the natural history of the disease or to maintain a stable 
remission over time [7]. Population-based studies show that, using the conven-
tional therapies, only 42% of the patients with CD are symptom free 2 years after 
initial diagnosis and only 12% after 10 years. Besides this, 10% of patients have 
continuously active disease at 2 years after initial diagnosis and 1% at 10 years 
[8]. Since steroids cannot be used as maintenance therapy for remission, immu-
nosuppression with thiopurinic agents, such as azathioprine, mercaptopurine 
or methotrexate have been widely used, even though all have limited value for 
induction of remission and can only benefit less than half of the patients who 
suffer from steroid dependency or resistance [9]. Resection of the inflamed bowel 
does not interrupt the progression of the disease in CD patients [8]. Cosnes et al. 
investigated the need for intestinal surgery from 1987 up to 2002 [10]. Although 
the 5-year cumulative probability of the immuno suppressant use increased from 
0.13 to 0.56, the cumulative risk of intestinal surgery remained unchanged over 
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time [10].
Anti-TNF-a therapy proved to be a potent treat-
ment for IBD; however, in 30% of patients it is not 
effective and a substantial proportion of patients 
may experience loss of response and/or side-effects 
[11–14], which often make surgery unavoidable. As such, 
expanding our therapeutic arsenal is still necessary.
It takes many years for potential drugs to enter 
human phase clinical trials. Even after reaching 
this phase, many drugs will never reach the market. 
Currently, discussion arises on the optimal trial design 
in IBD. In this review we will try to elucidate reasons 
for discontinuing trials and based on this knowledge 
will give some recommendations for designing future 
trials in IBD patients. 
Materials & methods
The Clinicaltrials.gov website [101] was searched for 
trials listed under the conditions ‘Crohn’s disease’ 
and/or ‘colitis, ulcerative’ between July 1996 and 
October 2011. Only inter ventional studies on new 
(unregistered) treatments were included. Nondrug 
trials (dietary supplements, pro biotics, devices and 
stem cells) were excluded. Also excluded were trials 
where there was no follow-up reported within the last 
2 years. 
According to the trial Phase (I, II, III) the trials 
were further divided into: completed, ongoing, dis-
continued and unknown. Only discontinued trials 
were further studied. The Pubmed database was used 
for finding full publications regarding the indentified 
trials with the following search criteria:  ..(the drug).. 
AND IBD, or ..(the drug).. AND inflammatory bowel 
disease, or ..(the drug).. AND Crohn’s disease, or ..(the 
drug)..AND ulcerative colitis, or ..(the drug) AND 
colitis. The presented abstracts of the DDW 2011 con-
gress and the ECCO 2011 congress were searched for 
unpublished data on the identified drugs. 
Results
For CD 405 clinical trials were identified, of these 113 
investigated new drugs. For nine trials no follow-up 
results were available and were thus excluded (Figure 1). 
For UC 282 clinical trials were identified, of which 78 
concerned researching new drugs. Due to absence of 
follow-up results five trials were excluded (Figure 2). 
Trials with an unknown phase were excluded as well. 
Combination trials (i.e., Phase I/II and Phase II/III 
 trials) were included.
Overview of discontinued trials
Thirty-four Phase I trials were identified (Figure 3), 13 
were combined Phase I/II trials. Four trials (two CD/
two UC/two combined Phase I/II) were discontin-
ued and included for further ana lysis. The drugs 
researched in these Phase I trials were sargramostim, 
givinostat, RhIL-11 and GI-270384. 
In Phase II, 123 trials were commenced according 
to clinicaltrials.gov. Of these, 13 were Phase I/II tri-
als and another 13 were Phase II/III, the remaining 
were true Phase II trials. A total of 18 trials (nine CD/
nine  UC) were discontinued. Two were Phase  I/II 
and three were Phase II/III. Researched drugs were 
sargramostim, tetomilast, AIN-457, semapinod, 
brakinumab, ITF-2357, SB-656933, visilizumab, 
basiliximab, riverprost, golimumab and retard release 
phos phatidylcholine and IFN-b-1a.
For Phase  III trial, 46  trials were identified 
(Supplementary Table 1). In total, 13 were combined 
Phase II/III trials. A total of seven trials were discon-
tinued. Of these trials, three were CD, four were UC 
and four trials were Phase II/III trials. Researched 
drugs were sagramostim, abatacept, visilizumab, 
golimumab and retard release phosphatidylcholine. 
In total, 24 discontinued trials on new drugs were 
included, of which two were Phase  I/II and three 
were Phase II/III. The 24 trials were on 16 different 
new drugs. Lack of efficacy was the reason for trial 
 discontinuation in 10 out of 16 treatments (62.5%). 
Discussion
In total, 191 trials on novel drugs were mentioned on the 
Clinicaltrials.gov website [101], 24 (12.6%) were inter-
rupted. The most common reason for discontinuation 
Figure 1. Discontinued trials in Crohn’s disease. All trials on 
ClinicalTrials.gov listed under Crohn’s disease. Of these trials, 113 trials 
were on new drugs. New drug trials were subdivided according to trial 
phase, and further divided into completed trials (C ), ongoing trial (O), 
discontinued trials (D) and trial status unknown (U).
New drug trials 113
Phase III  29
C 12, O 11, D 3, U 3
Phase I 19
C 11, O 5, D 2, U 1
Phase II 72




C 0, O1, D 0, U 1
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was lack of efficacy (Supplementary Table 1). Further 
ana lysis of these discontinued trials led to questions 
regarding the current trial design, such as; how to 
translate results from animal studies to patient popu-
lations, and, is it feasible to start treatment with drugs 
while still unaware of the full safety profile?
New treatments are designed in laboratories and 
translated to humans based on a positive effect found 
in cell lines and animal models. However, these 
positive results cannot be readily translated to the 
patient, and can even lead to deleterious effects. For 
example, murine anti-CD3 antibody, OKT 3, showed 
side-effects associated with severe systemic cyto-
kine release  [15]. In addition, although visilizumab 
has been altered to specifically bind to human CD3 
expressed on T-cells leaving the quiescent T-cells 
unchanged in vitro, a Phase I study of visilizumab 
demonstrated at least one adverse event in the major-
ity of patients, with a quarter experiencing severe 
adverse events [16,17]. Another challenge is the effec-
tiveness of drugs: IL-11 decreased histological as 
well as clinical activity of colitis in animals, but in 
humans this drug was only effective in a subset of 
CD patients [18,19], which shows that results of animal 
studies can also be applicable only for a group of our 
patients. Issues considering effectiveness were also 
seen investigating tetomilast. Although effective on 
the bench, UC patients did not improve compared 
with the placebo-treated patients [20,21]. Similar are 
the results of trials in sargra mostim. This drug was 
found to be effective in mice [22], but the same effect 
could not be confirmed in humans [23,24]. Another 
problem faced, is that various models are used for 
investigating drugs, leading to difficulties in com-
paring outcomes. This is illustrated by the fact that 
IL-17a knockout mice and IL-17RA knockout mice 
showed less inflammation after treatment with a 
neutralizing anti-IL-17A antibody [25,26], but anti-
IL-17a antibodies showed worsening of disease in 
mice with dextran sulfate sodium colitis [27]. In line 
with this are the results of rivenprost. In animals, 
both an EP4R agonist and an antagonist turned out 
to have an immunosuppressive effect [28,29]. A trial in 
humans was started before results of the antagonist 
were known and rivenprost was found to be ineffec-
tive in humans. Overall these results demonstrate 
that models for diseases come with restrictions and 
the pathogenesis of inflammation in these models 
does not adequately resemble IBD patients. 
Future perspective 
An even closer collaboration between workers on 
the bench and workers at the bedside is advocated to 
overcome problems such as those described above. 
However, future trial design also needs to be redi-
rected to implement other earlier published results 
on trial design. Poynard et al. looked at the survival 
of truth of clinical con clusions in articles on cirrhosis 
and hepatitis and found the half-life to be 45 years, 
similar to an earlier published report [30,31]. The 
authors did not find a beneficial survival benefit for 
either randomized trials or meta-ana lysis. The big-
gest weight (four-times more than other trials) was 
given to negative trials where patients with severe 
disease were mixed with patients without severe 
disease. In order to provide a trial with true power, 
future trial cohorts should resemble the patient pop-
ulation, including their genetic heterogeneity [32–35]. 
This heterogeneity may explain that the effect of new 
drugs can differ in each individual patient. Recently 
we showed that granulocytes of CD patients with a 
specific genetic defect are less sensitive to stimula-
tion with GM-CSF. Therefore a small proportion 
of patients without this defect may actually benefit 
from GM-CSF treatment [36]. Also trials on IFN-b-1a 
show similar results. At first, IFN-b-1a did not seem 
to be effective in either CD nor UC [37,38]. However, 
after looking at the results more closely, Croatian 
and Russian patients did have high remission and 
response rates using this treatment, while western 
Figure 2. Discontinued trials in ulcerative colitis. All trials on 
ClinicalTrials.gov listed under ulcerative colitis. Of these trials, 78 trials 
were on new drugs. New drug trials were subdivided according to trial 
phase, and further divided into completed trials (C), ongoing trial (O), 
discontinued trials (D) and trial status unknown (U).
New drug trials 78
Phase III  17
C 8, O 3, D 4,  U 2
Phase I 15
C 7, O 5, D 2, U 1
Phase II 51
C 27, O 13, D 9, U 2
Phase IV 4
C 2, O 2, D 0, U 0
Ulcerative colitis 282
Phase unknown 4
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European sites experienced the opposite [38]. Mannon 
et al. showed UC patients who did not respond to the 
treatment, to have high baseline levels of IL-17 and 
IL-6 production [39]. To further explore this diversity 
in IBD, in study populations the genetic variants and 
biologic markers could be used to stratify groups of 
patients, and will eventually lead to a personalized 
treatment model in IBD. 
For safety issues, a new drug does have to be studied 
extensively. However, when tested against placebo 
only, the actual effect compared with standard therapy 
Executive summary
Background 
 ■ Anti-TNF-a drugs are very potent for the majority of our inflammatory bowel disease patients but the current therapeutic arsenal 
still does not fully fulfill the therapeutic needs of our patients. However, many drugs will never reach the market. We elucidate 
pitfalls in clinical trials and offer recommendation for future research. 
Materials & methods
 ■ On ClinicalTrials.gov interventional trials on novel therapies that could be of interest for the treatment of inflammatory bowel 
disease were reviewed. Included were discontinued trials mentioned under the conditions listed under the terms ‘Crohn’s disease’ 
and/or ‘colitis, ulcerative’. The trials were started between July 1996 and October 2011. After inclusion of the most potent trials 
Pubmed was searched for full publication of these trials. Abstracts presented on the DDW 2011 congress and the ECCO 2011 
congress were searched for unpublished data on the found drugs. 
Results
 ■ 191 novel drug trials were published on ClinicalTrials.gov, of which 24 (12.6%) were discontinued. The most common reason for 
discontinuation was lack of efficacy.
Conclusion
 ■ Translating from bench to bedside is not always feasible. Animal models come with restrictions. In the future, personalized 
medicine based on a patient genetic profile will become important. Knowledge about interrupted trials is necessary to conduct 
high quality new drug trials in the future.
New drug trials 191
Phase III  46
C 20, O 14, D 7, U 5
Phase I 34
C 18, O 10, D 4, U 2 
Phase II 123
C 67, O 32, D 18, U 6
Phase IV 6
C 2 , O 3, D 0, U 1
UC + CD 687
Phase unknown 7
Figure 3. Total discontinued trials in inflammatory bowel disease. Total 
number of trials on ClinicalTrials.gov, listed under either CD or UC and 
the total number of trials on new drugs. The subdivision was the same as 
shown in the previous figures.
is unknown. Currently the placebo effect in CD and 
UC is well known and can be influenced by adjusting 
the study design, for instance [40–45]. Today, the stan-
dard design for developing new therapies are studies 
based on superiority tests in which a new therapy is 
compared with a control or current standard of care in 
a randomized setting with the aim of improving effi-
cacy. Future design should incorporate comparisons 
of new therapy, not only with placebo, but also to the 
current therapy standard in a three-arm design [46].
Currently, there is a suboptimal climate for pub-
lication when it comes to new drugs. Only a quarter 
of studies on new drugs are published at the time of 
market authorization and the majority of those are 
studies with positive findings [47]. The pharmaceuti-
cal industry also plays a large role in designing, con-
ducting and discontinuation of trials on new drugs. 
The industry would rather see trials on promising 
drugs published, since negative results might nega-
tively affect drug sales. This is understandable from 
their point of view. However, in order to provide the 
best possible patient care, the negative results are 
also worth mentioning, as has been proved earlier in 
this paper. To resolve this problem, someone, either 
a regulator, or an independent board, should be able 
to require submission of full trial data. This person or 
board should also be able to enforce sharing all avail-
able data [48]. This policy will not only improve the 
quality of newly conducted drug trials, but will also 
facilitate the comparison of new and existing drugs.
Conclusion
Of the 16  drugs investigated in the discontinued 
trials, ten did lack efficacy in IBD patients, despite 
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the promising results in models. This shows the dif-
ficulties in translating results from bench to bedside. 
Therefore, stronger collaboration between bench and 
bedside  workers is required. 
In the future, the cohorts must be a resemblance 
of the patient population, since these trials have a 
longer truth survival. Furthermore, genetics will 
start playing a bigger role and the role for the pla-
cebo-compared testing will become less significant. 
Personalized medicine based on a patient genetic 
profile and biologically important pathways are the 
future in IBD. Truth survival comes with change in 
trial method ology. Knowledge about interrupted tri-
als is necessary to  conduct high quality new drug tri-
als in the future.
Supplementary data
Supplementary data accompanies this paper and can 
be found at www.future-science.com/doi/suppl/10.4155/
CLI.11.185
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